Related Experiment Video

Updated: Mar 13, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K

Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. Reply

Fadi Fakhouri1, Carla M Nester2

  • 1University of Lausanne, Lausanne, Switzerland.

The New England Journal of Medicine
|March 11, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.0K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.0K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.7K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

570
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
570
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

293
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
293

Articles linked to this work by shared authors, journal, and citation graph.

Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulation.

bioRxiv : the preprint server for biology·2026

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Advances in therapy·2026

Impact of Disease Recurrence and Outcomes following Kidney Transplantation for Glomerulonephritis: A Prospective Nationwide Cohort Study.

Kidney360·2026

Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.

Clinical journal of the American Society of Nephrology : CJASN·2026

Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis.

Kidney international reports·2026

[Nephrology : what's new in 2025].

Revue medicale suisse·2026

Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis.

The New England journal of medicine·2026

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

The New England journal of medicine·2026

Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.

The New England journal of medicine·2026

Eplontersen for Transthyretin Amyloid Cardiomyopathy.

The New England journal of medicine·2026

Myeloproliferative Neoplasms.

The New England journal of medicine·2026

Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.

Cureus·2026

Granulomatous Interstitial Nephritis With Perivascular Involvement in Carbamazepine-Induced DRESS Syndrome: A Case Report.

Kidney medicine·2026

Additive effect of Ruta graveolens bioactive phytoconstituents and cisplatin through PKC/MEK/ERK pathway in glioblastoma.

Molecular therapy. Oncology·2026

Challenges and approaches to the design of hydrophilic linkers for antibody-drug conjugates.

Journal of controlled release : official journal of the Controlled Release Society·2026

Dissecting Cellulitis and Hidradenitis Suppurativa: Two Diseases or One Follicular-Occlusion Spectrum?

International journal of dermatology·2026

Effect of sugar modifications on the solution stability of nucleoside phosphoramidites.

Nucleosides, nucleotides & nucleic acids·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us